CL2024003442A1 - Agentes aglutinantes 5t4 y usos de los mismos - Google Patents

Agentes aglutinantes 5t4 y usos de los mismos

Info

Publication number
CL2024003442A1
CL2024003442A1 CL2024003442A CL2024003442A CL2024003442A1 CL 2024003442 A1 CL2024003442 A1 CL 2024003442A1 CL 2024003442 A CL2024003442 A CL 2024003442A CL 2024003442 A CL2024003442 A CL 2024003442A CL 2024003442 A1 CL2024003442 A1 CL 2024003442A1
Authority
CL
Chile
Prior art keywords
binding agents
antibodies
antibody
present disclosure
disclosure provides
Prior art date
Application number
CL2024003442A
Other languages
English (en)
Spanish (es)
Inventor
Kantak Seema
Hammer Bonnie
N Higaki Jeffrey
Kaplan Charles
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of CL2024003442A1 publication Critical patent/CL2024003442A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2024003442A 2022-05-13 2024-11-11 Agentes aglutinantes 5t4 y usos de los mismos CL2024003442A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263341944P 2022-05-13 2022-05-13

Publications (1)

Publication Number Publication Date
CL2024003442A1 true CL2024003442A1 (es) 2025-02-28

Family

ID=88731098

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2024003442A CL2024003442A1 (es) 2022-05-13 2024-11-11 Agentes aglutinantes 5t4 y usos de los mismos
CL2025002572A CL2025002572A1 (es) 2022-05-13 2025-08-26 Anticuerpo anti-5t4; composición farmacéutica que lo comprende; y su uso.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2025002572A CL2025002572A1 (es) 2022-05-13 2025-08-26 Anticuerpo anti-5t4; composición farmacéutica que lo comprende; y su uso.

Country Status (16)

Country Link
US (1) US20250326858A1 (enExample)
EP (1) EP4522660A4 (enExample)
JP (1) JP2025518493A (enExample)
KR (1) KR20250024530A (enExample)
CN (2) CN120607619A (enExample)
AU (1) AU2023267764A1 (enExample)
CA (1) CA3252305A1 (enExample)
CL (2) CL2024003442A1 (enExample)
CO (1) CO2024015383A2 (enExample)
CR (1) CR20240489A (enExample)
DO (1) DOP2024000234A (enExample)
IL (1) IL316788A (enExample)
MX (1) MX2024013871A (enExample)
PE (1) PE20251275A1 (enExample)
TW (1) TW202400639A (enExample)
WO (1) WO2023220626A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025180472A1 (zh) * 2024-02-28 2025-09-04 惠和生物技术(上海)有限公司 单克隆抗体分子及其用途
US20260008868A1 (en) * 2024-07-05 2026-01-08 Solve Therapeutics, Inc. 5t4-binding proteins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ596295A (en) * 2006-03-10 2013-01-25 Wyeth Corp Anti-5T4 antibodies and uses thereof
CA2959694C (en) * 2014-09-04 2023-11-21 Cellectis Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
CN114025797A (zh) * 2019-05-31 2022-02-08 昆士兰医学研究所理事会 抗Gal9免疫抑制性结合分子

Also Published As

Publication number Publication date
EP4522660A2 (en) 2025-03-19
PE20251275A1 (es) 2025-05-14
WO2023220626A3 (en) 2023-12-14
IL316788A (en) 2025-01-01
CL2025002572A1 (es) 2025-10-03
WO2023220626A2 (en) 2023-11-16
KR20250024530A (ko) 2025-02-18
MX2024013871A (es) 2024-12-06
US20250326858A1 (en) 2025-10-23
AU2023267764A1 (en) 2024-11-21
CN119546643A (zh) 2025-02-28
CR20240489A (es) 2025-01-07
CN120607619A (zh) 2025-09-09
DOP2024000234A (es) 2025-02-28
TW202400639A (zh) 2024-01-01
JP2025518493A (ja) 2025-06-17
EP4522660A4 (en) 2026-04-29
CA3252305A1 (en) 2023-11-16
CO2024015383A2 (es) 2025-02-04

Similar Documents

Publication Publication Date Title
CO2024015383A2 (es) Agentes aglutinantes 5t4 y usos de los mismos
CL2024001473A1 (es) Conjugados de fármacos y anticuerpos anti-ccr7
CL2020000263A1 (es) Conjugado de anticuerpo monoclonal contra bcma-fármaco.
CL2021002242A1 (es) Proteínas de unión condicionalmente activadas restringidas (divisional de la solicitud no. 202000570)
CL2023003607A1 (es) Anticuerpos anti-ccr8 y usos de los mismos
MX374810B (es) Anticuerpos 4-1bb anti-humano y usos de los mismos
MX2022014125A (es) Anticuerpos y conjugados de los mismos.
PE20201464A1 (es) Conjugados anticuerpo anti-cd40-farmaco
MX2019005879A (es) Enlazadores que contienen peptido para conjugados anticuerpo-farmaco.
MX381760B (es) Tintas cerca de infrarrojo (nir) dirigidas por antìgeno prostàtico especìfico de membrana (psma) y sus usos.
MX2022010515A (es) Conjugacion mediada por transglutaminasa.
EA201890158A1 (ru) Антитела против ntb-a и связанные композиции и способы
MX2020010104A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado.
BR112023014128A2 (pt) Conjugados de anticorpo-fármaco imunomodulatórios
CO2020014343A2 (es) Anticuerpos específicos para cd3 y sus usos
CO2018004152A2 (es) Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso
MX2022006132A (es) Anticuerpos anti alfa-v beta-6 (avb6) y conjugados de anticuerpo-farmaco.
AR104987A1 (es) Inmunoconjugados anticuerpo-fármaco unidos por enlazadores no peptídicos
BR112017022252A2 (pt) conjugados de anticorpo-droga sítio-específicos
CO2024015381A2 (es) Conjugados anticuerpo-fármaco 5t4 y usos de los mismos
UY37669A (es) Conjugados de fármaco-anticuerpo (adc) anti-prlr y usos de los mismos
CL2021002838A1 (es) Anticuerpo anti-bcma conjugado, composiciones que comprenden el mismo, y métodos de fabricación y uso del mismo.
MX2023009146A (es) Anticuerpos y usos de estos.
MX2024002407A (es) Anticuerpos y conjugados sirp-alfa.
MX2024002720A (es) Nanocuerpos anti-4-1bb.